
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphetamine Sulfate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Product Name : Adzenys XR
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Amphetamine Sulfate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
